Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia

Blood

Volumn 121, Issue 8, 2013, Pages 1384-1393

  Diamanti, Paraskevi ^a,b   Cox, Charlotte V ^a,b   Moppett, John P ^c   Blair, Allison ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; PARTHENOLIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFANT; LEUKEMIA INITIATING CELL; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84874449432     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448852     Document Type: Article

References (46)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565.
2. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol. 2008;9(9):873-883.
3. Gaynon PS. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. Curr Hematol Malig Rep. 2007;2(3):193-201. (Pubitemid 47235570)
4. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature. 2007;446(7137):758-764. (Pubitemid 46582031)
5. Anderson K, Lutz C, Van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukemia. Nature. 2011;469(7330):356-361.
6. Notta F, Mullighan CG, Wang J C Y, et al. Evolution of human BCR-ABL1 lymphoblastic leukemia-initiating cells. Nature. 2011;469(7330):362-367.
7. Kager L. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia. JBUON. 2009;14:S181-S186.
8. Holleman A, Cheok MH, Den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-542.
9. Den Boer ML, Van Slegtenhorst M, De Menezes RX, et al. Asubtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
10. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95(3):1007-1013. (Pubitemid 30062725)
11. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood. 2004;104(9):2919-2925. (Pubitemid 39434980)
12. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood. 2007;109(2):674-682. (Pubitemid 46105969)
13. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood. 2009;113(14):3287-3296.
14. Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+ CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008;22(6):1207-1213. (Pubitemid 351833789)
15. Le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008;14(1):47-58. (Pubitemid 351885495)
16. Dick JE. Stem cell concepatients renew cancer research. Blood. 2008;112(13):4793-4807.
17. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138-152.
18. Diamanti P, Cox CV, Blair A. Comparison of childhood leukemia initiating cell populations in NOD/SCIDand NSG mice. Leukemia. 2012;26(2):376-380.
19. Chiu P P L, Jiang H, Dick JE. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood. 2010;116(24):5268-5279.
20. Gerby B, Clappier E, Armstrong F, et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia. 2011;25(8):1249-58.
21. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apo-ptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169. (Pubitemid 40720758)
22. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110(13):4427-4435. (Pubitemid 351377809)
23. Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia. 2006;20(6):1073-1079. (Pubitemid 43797300)
24. Hewamana S, Alghazal S, Lin TT, et al. The NF-kB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111(9):4681-4689.
25. Hassane DC, Sen S, Minhajuddin M, et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010;116(26):5983-5990.
26. Kim YR, Eom JI, Kim SJ, et al. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010;335(2):389-400.
27. Wiedhopf RM, Young M, Bianchi E, Cole JR. Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide. J Pharm Sci. 1973;62(2):345.
28. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed). 1985;291(6495):569- 573. (Pubitemid 15225459)
29. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis. 1989;48(7):547-549. (Pubitemid 19186590)
30. Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett. 2007;254(1):119-127. (Pubitemid 47058812)
31. Zunino SJ, Storms DH, Ducore JM. Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t (4;11). Int J Oncol. 2010;37(5):1307-1313.
32. Sweeney CJ, Mehrota S, Sadaria MR, et al. The sesquiterpene lactone Parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005;4(6):1004-1012. (Pubitemid 40909083)
33. Foka P, Irvine SA, Kockar F, Ramji DP. Interleukin-6 represses the transcription of the CCAAT/enhancer binding protein-agene in hepatoma cells by inhibiting its ability to autoactivate the proximal promoter region. Nucleic Acids Res. 2003;31(23):6722-6732. (Pubitemid 37508779)
34. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett. 1997;402(1):85-90. (Pubitemid 27056030)
35. Kordes U, Krappmann D, Heissmeyer V Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14(3):399-402. (Pubitemid 30142862)
36. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371(9617):1030-1043.
37. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 1997;272(23):14914-14920. (Pubitemid 27251763)
38. Avellino R, Romano S, Parasole R, et al. Rapa-mycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood. 2005;106(4):1400-1406. (Pubitemid 41129607)
39. Teachey D, Obzut D, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107(3):1149-1155. (Pubitemid 43156317)
40. Zeng Z, Sarbassovdos D, Samudio I, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109(8):3509- 3512. (Pubitemid 46572543)
41. Crazzolara R, Cisterne A, Thien M, et al. Potentiating effects of RAD001 (Everolimus) on vincris-tine therapy in childhood acute lymphoblastic leukemia. Blood. 2009;113(14):3297-306.
42. Evangelisti C, Ricci F, Tazzari P, et al. Targeted inhibition of mTORC1 and mTORC2 by activesite mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 2011;25(5):781-791.
43. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630-639. (Pubitemid 46224241)
44. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group Study. Clin Cancer Res. 2007;13(5):1516-1522. (Pubitemid 46450443)
45. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed acute lympho-blastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-259.
46. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD0001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica. 2011;96(1):69-77.